Patients’ preferences for surgical and adjuvant systemic treatment in early breast cancer: A systematic review.

Related Articles

Patients’ preferences for surgical and adjuvant systemic treatment in early breast cancer: A systematic review.

Cancer Treat Rev. 2014 Jun 23;

Authors: Hamelinck VC, Bastiaannet E, Pieterse AH, Jannink I, van de Velde CJ, Liefers GJ, Stiggelbout AM

PURPOSE: Treatment decisions in early breast cancer can revolve around type of surgery and whether or not to have adjuvant systemic therapy. This systematic review aims to give an overview of patient self-reported factors affecting preferences for breast conserving surgery (BCS) versus mastectomy (MAST), the minimal benefit patients require from adjuvant chemotherapy (aCT) and/or adjuvant hormonal therapy (aHT) to consider it worthwhile, and factors influencing this minimally-required benefit.
METHODS: PubMed and EMBASE were searched for relevant articles. Two reviewers independently selected articles and extracted data.
RESULTS: We identified 15 studies on surgical and six on adjuvant systemic treatment decision-making. Factors affecting patient preference for BCS most frequently related to body image (44%), while factors influencing preference for MAST most often related to survival/recurrence (46%). To make adjuvant systemic therapy worthwhile, the median required absolute increase in survival rate was 0.1-10% and the median required additional life expectancy was 1day to 5years. The range of individual preferences was wide within studies. Participants in the aHT studies required larger median benefits than those in the aCT studies. Factors associated with judging smaller benefits sufficient most often (44%) related to quality of life (e.g., less treatment toxicity).
CONCLUSION: Decisive factors in patients’ preferences for surgery type commonly relate to body image and survival/recurrence. Most participants judged small to moderate benefits sufficient to consider adjuvant systemic therapy worthwhile, but individual preferences varied widely. Clinicians should therefore consider the patient’s preferences to tailor their treatment recommendations accordingly.

PMID: 24986544 [PubMed – as supplied by publisher]

This entry was posted in Cancer Treat Rev and tagged . Bookmark the permalink.

Leave a Reply

Your email address will not be published. Required fields are marked *